These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1968250)

  • 21. Behavioural actions of neuroleptics are not reduced by hypophysectomy.
    Costall B; Fortune DH; Naylor RJ; Nohria V
    J Pharm Pharmacol; 1982 Sep; 34(9):588-90. PubMed ID: 6127386
    [No Abstract]   [Full Text] [Related]  

  • 22. Behavioural correlates to the dopamine D-1 and D-2 antagonists.
    Christensen AV; Arnt J; Hyttel J; Svendsen O
    Pol J Pharmacol Pharm; 1984; 36(2-3):249-64. PubMed ID: 6147830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo.
    Ichikawa J; Meltzer HY
    Brain Res; 1992 Mar; 574(1-2):98-104. PubMed ID: 1379112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipsychotic properties of new N-(4-substituted-1-piperazinylethyl)- and N-(4-substituted-1-piperidinylethyl)-phthalimides.
    al-Rashood KA; Mustafa AA; Alhaider AA; Ginawi OT; Madani AA; el-Obeid HA
    J Pharm Sci; 1988 Oct; 77(10):898-901. PubMed ID: 2907047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mesolimbic involvement with behavioural effects indicating antipsychotic activity.
    Costall B; Naylor RJ
    Eur J Pharmacol; 1974 Jun; 27(1):46-58. PubMed ID: 4604756
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of amperozide on the dopamine synthesis activity in the tuberoinfundibular neurons.
    Andersson G; Albinsson A; Pettersson G
    Arzneimittelforschung; 1990 Mar; 40(3):237-9. PubMed ID: 2111999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of the novel antipsychotic drug amperozide and its metabolite FG5620 with central nervous system receptors and monoamine uptake sites: relation to behavioral and clinical effects.
    Svartengren J; Pettersson E; Björk A
    Biol Psychiatry; 1997 Aug; 42(4):247-59. PubMed ID: 9270901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The interaction of clonidine with dopamine-dependent behaviour in rodents.
    Pycock CJ; Jenner PG; Marsden CD
    Naunyn Schmiedebergs Arch Pharmacol; 1977 Mar; 297(2):133-41. PubMed ID: 558529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux.
    Pehek EA; Meltzer HY; Yamamoto BK
    Eur J Pharmacol; 1993 Aug; 240(1):107-9. PubMed ID: 8405119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amperozide, a putative anti-psychotic drug: uptake inhibition and release of dopamine in vitro in the rat brain.
    Eriksson E
    Life Sci; 1990; 47(23):2111-7. PubMed ID: 1979998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Behavioural correlates of modified dopaminergic/anticholinergic responses following chronic treatment with neuroleptic agents of differing activity spectra.
    Costall B; Naylor RJ; Owen RT
    Eur J Pharmacol; 1978 Mar; 48(1):29-36. PubMed ID: 25189
    [No Abstract]   [Full Text] [Related]  

  • 32. ST2472: a new potential antipsychotic with very low liability to induce side-effects.
    Stasi MA; Di Serio S; Vertechy M; Schiavone A; Ghirardi O; Minetti P; Campiani G; Borsini F; Carminati P
    Int J Neuropsychopharmacol; 2008 May; 11(3):309-19. PubMed ID: 17925059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atypical antipsychotic drugs block selective components of amphetamine-induced stereotypy.
    Tschanz JT; Rebec GV
    Pharmacol Biochem Behav; 1988 Nov; 31(3):519-22. PubMed ID: 3251235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of some polyamines on putative behavioural indices of mesolimbic versus striatal dopaminergic function.
    Hirsch SR; Richardson-Andrews R; Costall B; Kelly ME; de Belleroche J; Naylor RJ
    Psychopharmacology (Berl); 1987; 93(1):101-4. PubMed ID: 2819921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of amperozide, a new antipsychotic drug, on plasma corticosterone concentration in the rat.
    Albinsson A; Andersson G
    Life Sci; 1992; 51(19):1535-44. PubMed ID: 1359366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory behaviour, exploration and locomotion following NMDA or 6-OHDA lesions in the rat nucleus accumbens.
    Weissenborn R; Winn P
    Behav Brain Res; 1992 Nov; 51(2):127-37. PubMed ID: 1466779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictability and specificity of behavioral screening tests for neuroleptics.
    Worms P; Lloyd KG
    Pharmacol Ther B; 1979; 5(1-3):445-50. PubMed ID: 40263
    [No Abstract]   [Full Text] [Related]  

  • 39. Influence of (-)-sulpiride and YM-09151-2 on stereotyped behavior in chicks and catalepsy in rats.
    Wambebe C
    Jpn J Pharmacol; 1987 Feb; 43(2):121-8. PubMed ID: 2883335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of dihydroergotoxine on some dopamine-related behaviors in rats.
    Flório JC; Palermo-Neto J
    Gen Pharmacol; 1990; 21(4):411-5. PubMed ID: 2379797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.